Cardiotoxicity mechanisms of antitumor therapy with immune checkpoint inhibitors: new achievements
The immune checkpoint inhibitors (ICTs) emergence has opened up new perspectives in cancer immunotherapy. Nevertheless, serious, including life-threatening conditions caused by ICT cardiotoxic effects pose a number of obstacles to clinical specialists. The lack of knowledge about pathophysiology of...
Saved in:
Main Authors: | L. D. Khidirova (Author), A. E. Latsvieva (Author), A. V. Vederin (Author) |
---|---|
Format: | Book |
Published: |
Столичная издательская компания,
2024-06-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Immune Response Checkpoint Inhibitors: New Risks of a New Class of Antitumor Agents
by: E. V. Shubnikova, et al.
Published: (2020) -
Immune Checkpoint Inhibitor-Associated Cardiotoxicity: Current Understanding on Its Mechanism, Diagnosis and Management
by: Yu-Wen Zhou, et al.
Published: (2019) -
Cardiotoxicity associated with immune checkpoint inhibitors: Current status and future challenges
by: Lu Gan, et al.
Published: (2022) -
Current understanding of the cardiotoxicity-related treatment of immune checkpoint inhibitors in breast cancer
by: Jiajing Dai
Published: (2023) -
Cardiotoxicity Induced by Immune Checkpoint Inhibitors: A Pharmacovigilance Study From 2014 to 2019 Based on FAERS
by: Chenxin Chen, et al.
Published: (2021)